Validation of candidate genes associated with cardiovascular risk factors in psychiatric patients

Prog Neuropsychopharmacol Biol Psychiatry. 2012 Mar 30;36(2):213-9. doi: 10.1016/j.pnpbp.2011.08.001. Epub 2011 Aug 6.

Abstract

The purpose of this study was to identify genetic variants predictive of cardiovascular risk factors in a psychiatric population treated with second generation antipsychotics (SGA). 924 patients undergoing treatment for severe mental illness at four US hospitals were genotyped at 1.2 million single nucleotide polymorphisms. Patients were assessed for fasting serum lipid (low density lipoprotein cholesterol [LDLc], high density lipoprotein cholesterol [HDLc], and triglycerides) and obesity phenotypes (body mass index, BMI). Thirteen candidate genes from previous studies of the same phenotypes in non-psychiatric populations were tested for association. We confirmed 8 of the 13 candidate genes at the 95% confidence level. An increased genetic effect size was observed for triglycerides in the psychiatric population compared to that in the cardiovascular population.

Trial registration: ClinicalTrials.gov NCT00752960.

Publication types

  • Multicenter Study
  • Research Support, N.I.H., Extramural
  • Validation Study

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Antipsychotic Agents / adverse effects
  • Antipsychotic Agents / therapeutic use
  • Body Mass Index
  • Cardiovascular Diseases / complications
  • Cardiovascular Diseases / genetics*
  • Cholesterol / blood
  • Female
  • Genetic Association Studies / methods*
  • Genetic Predisposition to Disease / genetics
  • Genotype
  • Humans
  • Male
  • Mental Disorders / blood
  • Mental Disorders / complications
  • Mental Disorders / drug therapy
  • Mental Disorders / genetics*
  • Middle Aged
  • Polymorphism, Single Nucleotide / genetics
  • Risk Factors
  • Triglycerides / blood

Substances

  • Antipsychotic Agents
  • Triglycerides
  • Cholesterol

Associated data

  • ClinicalTrials.gov/NCT00752960